Janssen’s Tecvayli (teclistamab-cqyv) Receives the US FDA’s Approval for the Treatment of Relapsed or Refractory Multiple Myeloma
Shots:
- The US FDA has approved Tecvayli (teclistamab-cqyv) for the treatment of adult patients with r/r MM prior received ≥4 prior lines of therapy including a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb
- In the P-II (MajesTEC-1) trial, the therapy showed ORR (61.8%) with CR (28.2%), and the median time to first response was 1.2mos. At a median follow-up of 7.4mos., the estimated DoR rate was 90.6% @6mos.and 66.5% @9mos., 78% received ≥4 prior lines of therapy, 76% were triple-class refractory
- Tecvayli is an off-the-shelf, SC therapy for patients with incurable blood cancer with limited treatment options. The product is supplied as 30mg/3mL and 153mg/1.7mL single-dose vials
Ref: PR Newswire | Image: Janssen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
